RTP Mobile Logo
Oncology Nursing Update, Multiple Myeloma Edition, Issue 1, 2014
Released February 2014

Featuring interviews with Dr Noopur Raje and Ms Kena C Miller. (Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY
    Multiple myeloma (MM) is a plasma cell neoplasm that accounts for approximately 10% of all hematologic cancers and carries with it the worst death to new cases ratio (3 to 4). Patients with advanced active disease require immediate induction therapy to prepare eligible candidates for autologous stem cell transplant (ASCT). Optimal induction therapy for both ASCT candidates and those not eligible for transplant remains an area of clinical controversy, and multiple acceptable treatment options appear to merit consideration. Recent clinical research demonstrates an abundance of treatment options now available to patients with both newly diagnosed and relapsed or refractory MM. Published results from ongoing trials continually lead to the emergence of new therapeutic regimens and changes in the use of existing treatments. To provide oncology nurses with therapeutic strategies to address the disparate needs of patients with MM, the Oncology Nursing Update audio series employs one-on-one interviews with medical oncologists and nurses who are experts in caring for patients with MM. Upon completion of this CNE activity, oncology nurses should be able to formulate an up-to-date and more complete approach to the care of patients with MM.

    PURPOSE STATEMENT
    To present the most current research developments in MM and to provide the perspectives of a clinical investigator and nurse practitioner on the diagnosis and treatment of MM.

    LEARNING OBJECTIVES

    • Evaluate the benefits and risks associated with systemic therapies used in the evidence-based treatment of MM, including chemotherapy regimens, proteasome inhibitors, corticosteroids and immunomodulatory drugs (IMiDs).
    • Develop a plan of care to manage the side effects associated with these therapies to support quality of life and continuation of treatment.
    • Recognize the recent FDA approvals of carfilzomib and pomalidomide, and identify clinical situations in which these agents may be appropriate therapeutic options.
    • Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with MM.

    ACCREDITATION STATEMENT

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    FOR SUCCESSFUL COMPLETION
    This is an audio CNE program. Participants should read the learning objectives and faculty disclosures and listen to the audio MP3s.

    CME credit is no longer available for this issue

    CONTENT VALIIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — Ms Miller had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr RajeAdvisory Committee: Amgen Inc, Celgene Corporation; Consulting Agreements: Lilly, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc; Contracted Research: Acetylon Pharmaceuticals Inc, Amgen Inc, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation.

    EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: AbbVie Inc, Algeta US, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS —
    The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Celgene Corporation, Millennium: The Takeda Oncology Company and Onyx Pharmaceuticals Inc.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date:
    February 2014
    Expiration date: February 2015

    There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Acknowledge and close

Listen to audio:
Oncology Nursing Update, Multiple Myeloma Edition, Issue 1, 2014
Released February 2014

Featuring interviews with Dr Noopur Raje and Ms Kena C Miller. (Audio Content)

Read print: